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Background: Delayed diagnosis and treatment of a polymorphonuclear cell (PMN)-predominant
pleural effusion due to Mycobacterium tuberculosis (MTB) are associated with poor outcome
and the risk of tuberculosis transmission. We investigated the clinical differences of PMN-
predominant pleural effusion due to MTB or other microorganisms.
Methods: From January 2000 to April 2007, a total of 354 patients with tuberculous pleurisy
were identified. Among them, 39 (11.0%) adults had PMN-predominant pleural effusion (MTB
group). Their clinical characteristics were compared with the 117 age-/gender-matched
controls (1:3) selected from 715 patients with PMN-predominant pleural effusion due to other
microorganisms.
Results: Among patients with PMN-predominant septic pleural effusion, 5.2% were due to MTB.
The in-hospital mortality rate in the MTB group was 36%, similar to that of the control group.
Sputum samples were culture-positive for MTB in 41%. Weight loss (pZ 0.006), initial leuko-
cyte count 11,000/mL (pZ 0.007), and poor clinical response to empirical antibiotics in
the first 3 days (pZ 0.002) were independent factors suggestive of tuberculous pleurisy. A
shift toward mononuclear cell predominance of pleural effusions within 1 week was signifi-
cantly associated with tuberculous pleurisy. In the MTB group, if anti-tuberculous treatment
was started more than 14 days after the initial visit, there was a worse prognosis
(pZ 0.034). Among those with delayed treatment, 96.2% had finding(s) suggestive of tubercu-
lous pleurisy.2 23562905; fax: þ886 2 23582867.
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PMN-predominant tuberculous pleural effusion 821Conclusions: A high index of clinical suspicion can identify MTB in about 5.2% of patients pre-
senting with PMN-predominant septic pleural effusions. Awareness of the clinical pointers can
lead to early diagnosis and improved clinical outcome.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The differential cell count of pleural effusion is useful in
suggesting the etiology. Clinically, when poly-
morphonuclear cell (PMN) predominates, it is most
commonly due to an acute process, such as para-pneumonic
effusion or empyema. On the other hand, pleural effusion
with mononuclear cell predominance indicates a chronic
disease process, such as malignancy or tuberculous pleu-
risy.1 From these, it is easy to overlook PMN-predominant
pleural effusion from early tuberculosis (TB), leading to
delays in diagnosis and treatment. In one study on extra-
pulmonary TB, mainly tuberculous pleurisy, prolonged
hospital stay was associated with a delay in diagnosis.2
Moreover, sputum samples are culture-positive for Myco-
bacterium tuberculosis (MTB) in up to 52% of patients with
tuberculous pleurisy, even in those without lung paren-
chymal abnormalities on chest radiograph.3 Thus, about
half of the patients with tuberculous pleurisy are infectious
before adequate treatment.
As such, early diagnosis and treatment are clinically
important both in improving patient outcome and in pre-
venting further transmission. Therefore, understanding the
clinical factors suggestive of tuberculous pleurisy in
patients with PMN-predominant septic pleural effusion is
crucial. In this study, differences in the clinical character-
istics between PMN-predominant pleural effusion due to
MTB and other bacterial pathogens were analyzed.Materials and methods
Study population
This retrospective study was conducted in National Taiwan
University Hospital, a 2000-bed tertiary-care referral
center in northern Taiwan, where the incidence of TB from
2000 to 2005 was 77.0 to 99.7 per 1,000,000.4 The study was
approved by the institutional review board and informed
consent was deemed not necessary. We searched the
bacteriology and histopathology database from January
2000 to April 2007 and identified 354 adult patients (age
18 years) with newly diagnosed tuberculous pleurisy
(Figure 1). The diagnosis was established if (1) culture of
the pleural effusion or pleura tissue yielded MTB; (2)
histologic examination of the pleura biopsy revealed gran-
ulomatous inflammation and MTB was isolated from other
sites; or (3) histologic examination of the pleura biopsy
revealed granulomatous inflammation and there was
a clinical response to anti-tuberculous treatment. Among
them, 39 patients whose pleural effusions were PMN-
predominant, defined as the percentage of PMN more than
that of the mononuclear cell in differential cell count
analysis, were selected for further analysis (MTB group).
For each, three age- and gender-matched patients (samegender and age difference less than 5 years) were selected
from the 715 patients with PMN-predominant pleural effu-
sion due to pathogens other than M. tuberculosis identified
in the bacteriologic database as the control group
(Figure 1). Therefore, a total of 156 patients were included
for further analysis.
Study design
The medical records of each patient were reviewed to
collect the clinical characteristics, radiologic and labora-
tory findings, treatment, and outcome. Chest images,
including radiographs and computed tomography (CT)
scans, were independently reviewed by a pulmonologist
and a radiologist. If a discrepancy was noted between their
interpretations, the image was further reviewed by another
pulmonologist blinded to the results.
Respiratory symptoms were defined as cough, dyspnea,
pleuritic chest pain, or hemoptysis. Constitutional symp-
toms included fever, malaise, poor appetite, and weight
loss, which was defined as 10% weight reduction within
6 months. Acid-fast smear (AFS) and mycobacterial culture
were performed as previously described.5 Polymerase chain
reaction for TB (TB-PCR) was performed by using Cobas
Amplicor MTB (PCR, Roche Molecular System, Inc.). Anti-TB
treatment was considered late if it was started more than
14 days after the initial visit (late-treatment sub-group).6
Poor clinical response was defined as deterioration of any
presenting symptoms, chest radiographic findings, or labo-
ratory data within 3 days after empirical use of antibiotics.7
The patients were followed-up for one year after the initial
visit or until they died.
Statistical analysis
Differences between the groups were analyzed using
univariate conditional logistic regression analysis. All
significant variables (p < 0.05) identified were then further
analyzed by using multivariate conditional logistic regres-
sion analysis. Survival curves for each variable were
generated using the KaplaneMeier method and were
compared by log-rank test.
Results
The clinical characteristics of the 156 patients are
summarized in Table 1. In the MTB group, the mean age was
65 years (range 19e89 years) and 67% were male. Under-
lying end-stage renal disease, the presenting symptoms,
and duration of symptoms were significantly different
between the two groups. Chest radiographic findings were
similar between the two groups. Laboratory findings,
including leukocytosis (or neutrocytosis), anemia, and
a lower white blood cell count (especially PMN) in the
pleural effusion were significantly associated the MTB group
Figure 1 Inclusion of the study subjects. MTB, Mycobacterium tuberculosis; PE, pleural effusion; PMN, polymorphonuclear cell;
TB, tuberculosis.
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group had follow-up studies for their pleural effusions
within 1 week. Significantly more patients in the MTB group
showed a shift towards mononuclear cell predominance in
their effusions (79% vs. 26% pZ 0.005).
In the MTB group, acid-fast smears for pleural effusions
and sputum samples were positive in 4 (10%) and 9 (23%)
patients, respectively. MTB was isolated from sputum in 16
(41%) patients. TB-PCR was performed in 4 (10%) patients
and all showed negative results. Susceptibility tests were
available in 36 MTB patients and showed isoniazid mono-
resistance in 3, streptomycin mono-resistance in 1, and
multi-drug resistance (defined as simultaneously resistant
to isoniazid and rifampicin) in 2.
Empirical, broad-spectrum intravenous antibiotics were
given initially in 149 patients (95.5%), including 36 (92%) in
the MTB group and 113 (97%) in the control group. Only one
(2.6%) patient in the MTB group and 6 (5.1%) patients in the
control group received a fluoroquinolone as empirical
antibiotics. Within 3 days, the clinical condition deterio-
rated (poor clinical response) in 26 (67%) in the MTB group
and 40 (34%) in the control group (pZ 0.001). In the MTB
group, the average time to anti-tuberculous treatment was
33 days after the initial visit (range 0e112 days), with only
13 (33%) treated within 14 days after the initial visit.
To identify clinical factors suggestive of TB, eight vari-
ables that were significantly different between the two
groups in univariate analysis were further analyzed using
multivariate conditional logistic regression. The results
showed that the independent factors were weight loss
(odds ratio (OR) 26.66, 95% confidence interval (CI)
2.51e282.70, pZ 0.006), initial white blood cell (WBC)
count 11,000/mL (OR 0.26, 95% CI 0.10e0.69, pZ 0.007),
and poor clinical response to empirical antibiotics in the
first 3 days (OR 6.52, 95% CI 1.95e21.84, pZ 0.002). Of all
patients, 81.2% had tuberculous pleurisy if they had weightloss; 48.5% if their WBC count was 11,000/mL; 39.9% if the
clinical response to empirical antibiotic use was poor; and
52.5% if their serial pleural effusion in 1 week shifted to
lymphocyte predominance.
Between the two groups, there was no significant
difference in the in-hospital mortality rate (14 (36%) in the
MTB group and 51 (44%) in the control group, pZ 0.456)
and in 1-year survival (Figure 2A, pZ 0.680). The leading
cause of in-hospital death was sepsis/multiple organ failure
(8 (57%) in the MTB group and 36 (71%) in the control
group), followed by respiratory failure (4 (29%) in the MTB
group and 8 (16%) in the control group).
For patients in the MTB group, the prognosis was
significantly worse in the late-treatment sub-group than in
the early-treatment sub-group (Figure 2B, pZ 0.034).
Fourteen (54%) of the 26 patients in the late-treatment sub-
group died within 1 year. The cause of death included
septic shock and respiratory failure without any bacterio-
logic evidence other than MTB infection in 4 and 3,
respectively. The cause was septic shock due to pathogens
other than MTB in 4, and due to co-infection by MTB and
other pathogen in 1. Another patient died of massive
gastrointestinal bleeding. The last patient died of sudden
collapse. Of the 14 patients, 9 died before the diagnosis of
TB was made and did not receive anti-TB treatment. In the
late-treatment MTB subgroup, 25 (96.2%) had clinical find-
ings suggestive of TB, including weight loss in 9 (34.6%),
initial WBC count 11,000/mL in 22 (84.6%), a shift toward
mononuclear cell predominance in pleural effusions within
1 week in 13 (50.0%), and poor clinical response to empir-
ical antibiotics in 15 (57.7%).
Three of the 13 patients in the early-treatment MTB sub-
group died. The cause of death was acute myocardial
infarct in one, lung cancer with obstructive pneumonitis in
one, and septic shock due to pathogens other than MTB in
the remaining one.
Table 1 Characteristics of the 156 patients with polymorphonuclear cells (PMN)-predominant septic pleural effusion.
Characteristics MTB group (%)
(nZ 39)
Control group
(%) (nZ 117)
p-value
Age >65 years 23 (59) 69 (59) 0.652
Males 26 (67) 78 (67) 1.000
Family contact with TB patients 2 (5) 0 (0) 0.994
Body mass index <18 kg/m2 7 (18) 19 (16) 0.881
Underlying diseases 29 (74) 95 (81)
Diabetic mellitus 11 (28) 29 (25) 0.655
Congestive heart failure 11 (28) 19 (16) 0.110
Chronic obstructive pulmonary disease 9 (23) 18 (15) 0.283
Malignancy 8 (20) 41 (35) 0.092
End-stage renal disease 7 (18) 8 (7) 0.035
Pneumoconiosis 2 (5) 0 (0) 0.994
Cirrhosis of liver 2 (5) 11 (9) 0.337
HIV seropositive 1 (3) 2 (2) 0.740
Use of immunosuppressantsa 2 (5) 16 (14) 0.156
Intravenous drug abuser 0 (0) 4 (3) 0.994
Previous surgery history
Gastrointestinal surgery 4 (10) 14 (12) 0.752
Organ transplantation 0 (0) 3 (3) 0.994
Symptoms at presentation
Respiratory symptoms 39 (100) 105 (90) 0.993
Cough 20 (51) 37 (32) 0.024
Constitutional symptoms 36 (92) 84 (72) 0.016
Weight loss 13 (33) 3 (3) 0.001
Consciousness change 7 (18) 16 (14) 0.517
Symptom duration >14 days 11 (28) 12 (10) 0.010
Chest imaging
Pattern
Alveolar consolidation 26 (67) 86 (74) 0.390
Multiple nodules or mass 9 (23) 18 (15) 0.275
Fibrocalcified infiltrates 8 (21) 15 (13) 0.239
Miliary shadowing 4 (10) 0 (0) 0.991
No parenchymal lesion 5 (13) 11 (9) 0.539
Pneumothorax 7 (18) 33 (28) 0.221
Involving upper lung field 6 (15) 10 (9) 0.235
Cavitation 3 (8) 11 (9) 0.739
HIV, human immunodeficiency virus; TB, tuberculosis.
a The indication for immunosuppressants was autoimmune disease in 10 and 2 each of organ transplantation, malignancy, pulmonary
disease, and acute respiratory distress syndrome.
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In all patients with culture-confirmed TB pleurisy, 11.0% has
PMN-predominant pleural effusion, accounting for 5.2% of
all patients with PMN-predominant septic pleural effusion.
The patients in the MTB group were older than those
reported in previous series of tuberculous pleurisy (mean
age 28e62 years).8e11 Moreover, three-fourths of the
patients in the MTB group had underlying co-morbidities.
Thus, our patients with tuberculous pleurisy and PMN-
predominant pleural effusion had a higher in-hospital
mortality rate (36%) than previous reports (9.7e28%).11e13
Compatible with our previous studies, 5,6,14 a delay in
anti-TB treatment of more than 14 days was associated with
a worse clinical outcome in 1 year of follow-up. A largenumber of tuberculous pleurisy patients (67%) with delayed
treatment could be another explanation for the high
mortality rate in the MTB group. The yield rate of acid-fast
smear (23%) and mycobacterial culture (41%) for sputum
samples in the MTB group were also high, similar to the
prospective study conducted by Conde et al.,3 which
implies that about half of the tuberculous pleurisy patients
were infectious. These emphasize the necessity of early
diagnosis and treatment for tuberculous pleurisy with PMN-
predominant pleural effusion to improve patient outcome
and prevent further TB transmission.
Although a prospective study comparing patients with
empyema due to MTB and other pathogens12 found that
malnutrition (defined as BMI <18.5 kg/m2) was significantly
associated with TB empyema, the analysis here revealed
Table 2 Laboratory results of the 156 patients with polymorphonuclear cells (PMN)-predominant septic pleural effusion.
Laboratory results MTB group (%)
(nZ 39)
Control group
(%) (nZ 117)
p-value
Blood tests
White blood cell count >11,000/mL 7 (18) 83 (71) <0.001
Absolute neutrophil count >10,000/mL 6 (15) 73 (62) <0.001
Absolute lymphocyte count >4500/mL 0 (0) 1 (1) 0.993
Absolute monocyte
count >500/mL
16 (41) 55 (47) 0.427
Hemoglobin <13.5 g/dL in males or <12.0 g/dl in females 30 (77) 105 (90) 0.040
Platelet count <150 K/mL 10 (26) 39 (33) 0.382
Sodium <135 mmol/L 17 (44) 64 (55) 0.247
C-reactive protein >10 mg/dL 17 (44) 70 (60) 0.076
Albumin <3.5 g/dL 33 (85) 108 (92) 0.923
Lactate dehydrogenase >570 U/L (normal <190) 17 (44) 35 (30) 0.936
Pleural effusion analysis
Bilateral pleural effusion 6 (15) 17 (15) 0.328
White blood cell count >10,000/mL 5 (13) 40 (34) 0.008
PMN count >10,000/mL 4 (10) 36 (31) 0.010
Mononuclear cells
count >10,000/mL
0 (0) 4 (3) 0.994
Lactate dehydrogenase >1000 U/L 20 (51) 70 (60) 0.056
Glucose <60 mg/dL 10 (26) 45 (39) 0.053
Total protein >5 g/dL 6 (15) 12 (10) 0.597
Presence of malignant cells 3 (8) 4 (4) 0.288
824 M.-T. Lin et al.that only weight loss, but not BMI or the proportion of
patients with underlying co-morbid diseases, was sugges-
tive of tuberculous pleurisy. This is probably because most
of the tuberculous pleurisy patients were seen in the early
stages of the disease, as evidenced by 72% with less than
14 days of symptoms. Therefore, they were less likely to be
seriously malnourished. This might also explain why the
duration of symptoms was significantly longer in patients
with tuberculous pleurisy in previous reports9,12 but not in
the multivariate analysis here.
Consistent with a previous study by Neves et al.,9 pleural
effusion WBC count was significantly lower in the MTB
group. However, the proportion of patients in the MTB
group with pleural effusion protein level higher than 5 g/dL
was lower than those reported in previous studies.8,11,15,16
The possible cause might be the presence of underlying co-
morbidities, such as congestive heart failure, end-stage
renal disease, and liver cirrhosis, resulting in excess fluid
shift into the pleural space, which subsequently diluted the
protein level.
However, multivariate analysis revealed that blood WBC
count (especially neutrophil count), rather than pleural
effusion WBC count, was an independent predictive factor
for tuberculous pleurisy. It might be that the former is
a better indicator of a systemic inflammatory process than
the latter. Similar to findings in previous reports,10,14 the
follow-up pleural effusion study within 1 week in a large
proportion of patients with tuberculous pleurisy demon-
strated a shift towards mononuclear cell predominance.
In our study, few patients received a fluoroquinolone as
empirical antibiotics because the recommended treatment
for para-pneumonic effusion or empyema in our hospital
was a 3rd generation cephalosporin or anti-pseudomonalpenicillin plus clindamycin.17,18 Therefore, more patients
with PMN-predominant pleural effusion due to MTB dete-
riorate after empirical antibiotics than those due to other
pathogens.6,19
The multivariate analysis revealed that weight loss,
blood WBC count 11,000/mL, and poor clinical response to
empirical antibiotics were independent predictive factors
for tuberculous pleurisy. In fact, almost every patient
(96.2%) in the late-treatment MTB sub-group had at least
one of these clinical clues. For early diagnosis and treat-
ment, further laboratory studies, including measurement of
adenosine deaminase (ADA),10 nucleic acid amplification
test for MTB,20 and interferon-gamma release assay,21
should be considered.
Our study reveals that none of the PMN-predominant
pleural effusion due to TB pleurisy was TB-PCR-positive. In
our hospital from 2000 to 2008, a total of 43 patients with
culture-confirmed TB pleurisy received TB-PCR for their
pleural effusion samples. Among them, only 3 (8%) in the 39
patients with lymphocyte-predominant pleural effusion had
a positive result (unpublished data). The low positive rate
probably has two explanations. First, patients with
advanced TB can usually be diagnosed by simply acid-fast
smear and mycobacterial culture. Only those with a less
extensive disease will undergo TB-PCR for the diagnosis of
TB. In other words, these patients usually probably have
a low mycobacterial load. Second, the effusion of TB
pleurisy is usually PMN-predominant in the early stage of
disease course and thus pauci-bacillary.
The major limitations of this study were its retrospective
nature, which could underestimate the incidence of tuber-
culous pleurisy. In addition, bias in patient selection prob-
ably existed because the study was conducted in a tertiary
Figure 2 Survival curves of the 156 patients with poly-
morphonuclear cells (PMN)-predominant septic pleural effu-
sions. (A) The MTB group compared to the control group; and
(B) within the MTB group, the early-treatment sub-group
(starting anti-tuberculous treatment within 14 days after the
initial visit) compared to the late-treatment sub-group. MTB,
Mycobacterium tuberculosis.
PMN-predominant tuberculous pleural effusion 825care referral center and only culture- or histology-confirmed
cases were included. Lastly, in the absence of post-mortem
studies or autopsy, the causes of death were uncertain.
Prospective studies are necessary to clarify these issues.
Conclusions
This study demonstrates that in 5.2% of patients, PMN-
predominant septic pleural effusion was due to tuberculous
pleurisy, with a high mortality rate (36%) and a high risk for
transmission. To avoid delays in diagnosis and treatment,
a higher index of suspicion is important when taking care of
such patients, especially those with an initial presentation
of weight loss, initial blood WBC count 11,000/mL, or poor
clinical response to empirical antibiotics in the first 3 days.
A follow-up study of the pleural effusion within 1 week,which might demonstrate a shift toward mononuclear cell
predominance, is recommended.
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